Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

BACKGROUND: We evaluated combined targeting with cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: The...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Argiris, A., Kotsakis, A. P., Hoang, T., Worden, F. P., Savvides, P., Gibson, M. K., Gyanchandani, R., Blumenschein, G. R., Chen, H. X., Grandis, J. R., Harari, P. M., Kies, M. S., Kim, S.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2013
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3525135/
https://ncbi.nlm.nih.gov/pubmed/22898037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds245
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires